COMMUNIQUÉS West-GlobeNewswire

IntelGenx Reports Second Quarter 2018 Financial Results
09/08/2018
SAINT LAURENT, Quebec, Aug. 09, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the second quarter ended June 30, 2018. [...]
ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
End-of-Phase 2 Meeting with the U.S. FDA on Gencaro Atrial Fibrillation Development Plan Completed; Single Additional Phase 3 Trial Planned to Support NDA Submission WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE [...]
Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview
09/08/2018
Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-track to initiate around year-end Recent Follow-on Offering and BARDA award provide cash [...]
Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress
09/08/2018
Company Progressing Neurology and Immunotherapy Clinical Programs Anticipates Achievement of Significant Execution Milestones in the Second Half of 2018 and Full Year 2019 to Advance the Development of its Platform [...]
argenx to Present at 2018 Wedbush PacGrow Healthcare Conference
09/08/2018
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe [...]
Kezar Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update
09/08/2018
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet [...]
The Joint Corp. Reports Second Quarter 2018 Financial Results
09/08/2018
- Increases Annual System-Wide Gross Sales 29%, Compared to Second Quarter 2017 - - Grows Revenue 26%, Compared to Second Quarter 2017 - - Reports Net Loss of $43,000, Compared to Net Loss of $1.0 Million in Second [...]
ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
09/08/2018
-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental [...]
Yield10 Bioscience Announces Second Quarter 2018 Financial Results
09/08/2018
WOBURN, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to achieve step-change improvements in crop yield to enhance global food security, today [...]
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
09/08/2018
BELBUCA ® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of $200 Million For [...]
Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results
09/08/2018
Conference Call Scheduled August 9, 2018 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a [...]
Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update
09/08/2018
MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic [...]
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
09/08/2018
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019 Lead IND program for Alpha-1-antitrypsin deficiency (“A1AT”) expected to commence IND-enabling studies in second half of [...]
Resonant Inc. Reports Second Quarter 2018 Financial Resultsand Provides Business Update and Financial Outlook
09/08/2018
- Secured two new customer engagements - - Increased number of devices under contract to more than 60 - - Grew number of devices under qualification to 14 - GOLETA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Resonant Inc [...]
Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights
09/08/2018
Gimoti ™ NDA submitted to FDA on June 1 st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif., Aug. 09, 2018 (GLOBE [...]
KemPharm, Inc. Reports Second Quarter 2018 Results
09/08/2018
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced top line results from KP415.E01 efficacy and safety trial in children with ADHD [...]
Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results
09/08/2018
Company Enters Into Merger Agreement with Seelos Therapeutics, Inc. Apricus Shareholders Expected to Own ~14% of Combined Company Based on Estimated $90 Million Valuation at Closing Merger Expected to Close in Fourth [...]
Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
09/08/2018
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
09/08/2018
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over 20 years Top-line [...]

Pages